At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CNSP CNS Pharmaceuticals, Inc.
Market Closed 11-01 16:00:00 EDT
0.1126
+0.0010
+0.90%
盘后0.1144
+0.0018+1.60%
19:59 EDT
High0.1330
Low0.1088
Vol13.36M
Open0.1200
D1 Closing0.1116
Amplitude21.68%
Mkt Cap4.18M
Tradable Cap4.12M
Total Shares37.15M
T/O1.61M
T/O Rate36.55%
Tradable Shares36.55M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
CNS Pharmaceuticals Receives More Time to Regain Compliance With Nasdaq Listing Requirement
CNS Pharmaceuticals Q2 2024 Net Loss Reduced To $2.5M Due To Lower CRO Expenses; R&D Costs Decrease To $1.1M; G&A Expenses Increase To $1.4M Due To Higher Legal And Professional Fees
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.